Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Precision Biosciences (DTIL) EBT (2018 - 2025)

Historic EBT for Precision Biosciences (DTIL) over the last 8 years, with Q3 2025 value amounting to -$20.0 million.

  • Precision Biosciences' EBT fell 118.37% to -$20.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$86.0 million, marking a year-over-year decrease of 67631.56%. This contributed to the annual value of -$21.2 million for FY2024, which is 4466.82% up from last year.
  • According to the latest figures from Q3 2025, Precision Biosciences' EBT is -$20.0 million, which was down 118.37% from -$21.1 million recorded in Q2 2025.
  • Precision Biosciences' 5-year EBT high stood at $25.4 million for Q2 2024, and its period low was -$30.7 million during Q4 2021.
  • In the last 5 years, Precision Biosciences' EBT had a median value of -$13.9 million in 2022 and averaged -$12.8 million.
  • As far as peak fluctuations go, Precision Biosciences' EBT skyrocketed by 156480.41% in 2024, and later tumbled by 58247.26% in 2025.
  • Over the past 5 years, Precision Biosciences' EBT (Quarter) stood at -$30.7 million in 2021, then surged by 65.3% to -$10.7 million in 2022, then dropped by 28.0% to -$13.6 million in 2023, then crashed by 74.05% to -$23.7 million in 2024, then grew by 15.76% to -$20.0 million in 2025.
  • Its EBT was -$20.0 million in Q3 2025, compared to -$21.1 million in Q2 2025 and -$21.1 million in Q1 2025.